European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, MyelomaApril 23, 2024
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, MyelomaMarch 31, 2021
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, MyelomaAugust 14, 2023
FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, MyelomaAugust 22, 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, MyelomaSeptember 18, 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, MyelomaSeptember 22, 2023
